Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
Source:
Nasdaq GlobeNewswire
/
25 Apr 2022 06:00:01 America/Chicago
N/A
Share on,